Treat to Target in gout yields superior outcomes compared to Treat to Avoid Symptoms approach (results from Gout TrEatment Strategy (GO TEST) OVERTURE trial)

Description

Both the European League Against Rheumatism (EULAR) and the American College for Rheumatology (ACR) state that gout can be effectively managed by reducing sUA levels below the physiological threshold of saturation using Urate Lowering Therapy (ULT), a Treat to Target approach (T2T). An alternative, more reactive management strategy, advocated by the American College of Physicians (ACP) is to treat symptoms and to base the start and dosing of ULT on avoiding (recurrent) symptoms, without monitoring sUA levels. This treat-to-avoid symptom (T2S) approach has been criticized by rheumatologists for potentially ignoring ongoing urate deposition until potentially severe disease manifestations become apparent. Although the solid underlying mechanism of gout is ignored, the lack of a head-to-head comparison of both strategies led the ACP to advise the T2S strategy for the treatment of gout.

Period	7 Mar 2024
Event title	15th European Crystal Network Workshop 2024
Event type	Workshop
Conference number	15
Location	Paris, FranceShow on map
Degree of Recognition	International